Novo Nordisk A/S (NVO)

Market Cap	220.08B -39.8%
Revenue (ttm)	48.59B +6.4%
Net Income	16.10B +1.4%
EPS	3.62 +1.8%
Shares Out	4.44B
PE Ratio	13.74
Forward PE	14.39
Dividend	$1.23 (2.47%)
Ex-Dividend Date	Aug 18, 2025

Volume	24,902,927
Open	50.13
Previous Close	47.64
Day's Range	49.01 - 51.09
52-Week Range	43.08 - 93.80
Beta	0.40
Analysts	Hold
Price Target	54.25 (+9.07%)
Earnings Date	Feb 4, 2026

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers pro...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 69,505
• Stock Exchange: NYSE
• Ticker Symbol: NVO
• Website: https://www.novonordisk.com

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Analyst Summary

According to 10 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $54.25, which is an increase of 9.07% from the latest price.

Price Target

$54.25

(9.07% upside)

Analyst Consensus: Hold